 There will be 3 periods in this study: Screening period up to 14days, treatment period 11 months, follow-up period 1 month. At randomization visit patients will be randomized into one of the 2 treatment groups Group I ranibizumab 0.5 mg based on monthly treatment or Group II ranibizumab 0.5 mg based on TER randomization ratio of 1:1 and will receive the first dose of Investigational treatment. Patients in Group I the following visits will perform on monthly intervals. For patients in Group II the investigator will evaluate disease activity i.e., signs of exudation based on SD-OCT, and in case of absence of disease activity every next visit will be 2 weeks, with a maximum of a 12-week interval. 